Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Multimeric Oligonucleotide Synthesis & Conjugation

Custom synthesis of aptamer dimers, trimers, bispecific aptamers, antisense multimers, siRNA multimers, peptide-oligonucleotide conjugates and multifunctional oligonucleotide constructs for research, diagnostics, targeted gene therapy research and nanomedicine applications.

Aptamer Dimers & Trimers Bispecific Aptamers ASO & siRNA Multimers Peptide-Oligo Conjugates PEG / Peptide / Dendron Scaffolds HPLC / PAGE / SEC / MS QC
Request a Multimeric Oligo Quote Select by Application
Talk to a chemist Request a quote
Overview Formats Applications Capabilities Comparison Design Options Related FAQ Decision Guide Contact Literature
Overview

What Are Multimeric Oligonucleotides?

A multimeric oligonucleotide is a complex construct made of two or more synthetic nucleic acid sequences, aptamer domains or functional oligonucleotide modules joined into one molecular architecture.

These constructs may be linked by chemical bonds, PEG or spacer linkers, branched oligonucleotide architectures, dendron or dendrimer scaffolds, or peptide linkers and peptide scaffolds. They are used to improve target binding, recognize multiple targets, enhance delivery, increase local signal density and support targeted gene therapy and nanomedicine research.

Typical visual characteristics: multiple oligonucleotide domains, defined spacing between functional units, one or more linker/scaffold systems, and a multivalent molecular architecture.

Bio-Synthesis capabilities: aptamer dimers, aptamer trimers, bispecific aptamers, ASO multimers, siRNA multimers, aptamer-siRNA conjugates, aptamer-ASO conjugates, peptide-oligo conjugates, branched multimers and dendron-supported constructs.

Start Design Review How They Work
Multimeric Oligonucleotide
Aptamer • siRNA • ASO • Peptide
Targeted
Delivery
Gene
Modulation
Multivalent
Binding
Mechanism of Use

How Multimeric Oligonucleotides Work

Multimeric oligonucleotides bring multiple functional domains into proximity. The resulting construct can bind more strongly, recognize multiple targets, carry therapeutic modules or integrate targeting, delivery and detection functions.

Enhanced Binding

Two or more copies of the same aptamer or recognition motif can improve apparent binding strength through avidity effects.

Bispecific Recognition

Different domains can recognize separate targets, biomarkers, receptors or analytes within one molecule.

Targeted Delivery

A targeting aptamer, ligand or peptide can be joined to siRNA, ASO or another cargo-oriented oligo domain.

Multifunctional Design

Targeting, therapeutic, reporter and capture functions can be combined into one defined oligonucleotide construct.

Typical Construct Types

Visual Examples of Multimeric Oligonucleotide Formats

Multimeric oligonucleotides can be built as repeated binding domains, therapeutic oligo multimers or peptide-linked conjugates. These simple formats help distinguish application intent before selecting the final chemistry.

Aptamer Dimer / Trimer

Apt
Apt

Used to improve avidity, target retention and receptor engagement through repeated binding domains.

siRNA or ASO Multimer

siRNA
ASO

Used for multi-gene modulation studies, RNAi delivery research and therapeutic oligo development.

Peptide-Oligo Conjugate

Pep
Oligo

Used when cell penetration, peptide targeting, peptide scaffolding or peptide-mediated delivery is needed.

Application-Driven Selection

Select the Right Multimeric Strategy for Your Application

Choose the design based on the biological or analytical goal first. Architecture, linker chemistry and purification strategy can then be selected around that application.

Aptamer Dimer / Trimer

Aptamer - Linker - Aptamer

Multiple copies of the same aptamer can improve target engagement, local avidity and functional retention.

  • Enhanced binding and cell targeting
  • Diagnostic capture and receptor engagement
  • Linear, PEG-linked, branched or dendron-supported systems

Bispecific Aptamers

Aptamer A - PEG - Aptamer B

Two different aptamer domains can be linked to recognize separate targets, receptors or biomarkers.

  • Dual-target diagnostics
  • Cell targeting and receptor bridging
  • Multi-marker detection

Antisense Multimers

ASO B - Spacer - ASO B

Antisense multimer constructs can combine multiple ASO sequences or integrate ASO domains with targeting components.

  • Multi-gene regulation studies
  • Combination therapeutic research
  • Linear, PEG-linked or dendron-supported constructs

siRNA Multimers

Targeting Domain - siRNA

siRNA multimers may combine RNAi payloads with targeting ligands, aptamers, peptides or scaffold systems.

  • RNAi and targeted delivery research
  • Nanomedicine and platform development
  • Peptide-linked, PEG-linked or dendrimer-supported systems

Peptide-Oligo Conjugates

CPP - ASO / siRNA

Peptide linkers, peptide scaffolds or cell-penetrating peptides can connect domains, improve uptake or add targeting functionality.

  • CPP-siRNA and CPP-ASO conjugates
  • Aptamer-peptide constructs
  • Targeting peptide and therapeutic delivery systems

Multifunctional Constructs

Targeting - Therapy - Reporter

Targeting, therapeutic, capture and reporter modules can be combined in one construct for advanced diagnostic or therapeutic research.

  • Theranostics and imaging research
  • Capture + detection systems
  • Custom hybrid architectures
Bio-Synthesis Capabilities

Custom Multimeric Oligonucleotide Capabilities

Bio-Synthesis supports custom multimeric oligo design from domain layout and linker selection through synthesis, conjugation, purification and analytical release.

Aptamer-Based Constructs

  • Aptamer dimers
  • Aptamer trimers
  • Aptamer multimers
  • Bispecific aptamers

Therapeutic Oligo Multimers

  • Antisense multimers
  • siRNA multimers
  • Aptamer-siRNA conjugates
  • Aptamer-ASO conjugates

Conjugation-Based Systems

  • Peptide-oligonucleotide conjugates
  • PEG-linked oligonucleotides
  • Click chemistry constructs
  • Thiol / maleimide conjugates

Scaffold-Supported Designs

  • Branched multimeric oligos
  • Dendrimer-supported multimers
  • Multifunctional oligo constructs
  • Reporter and capture systems
Architecture Clarification

Multimeric vs Branched vs Dendrimeric Oligonucleotides

These terms overlap, but they are not the same. Multimeric describes multiple oligonucleotide domains or binding units. Branched and dendrimeric describe how those domains may be physically arranged.

Architecture Primary Meaning Typical Form Best For
Multimeric Oligonucleotide Two or more oligo domains, aptamers or recognition motifs in one construct Linear, PEG-linked, peptide-linked, branched or scaffold-supported Aptamer dimers/trimers, ASO/siRNA multimers, bispecific aptamers
Branched Oligonucleotide Multiple arms extend from a branch point Doubler, Trebler, 5-Me-dC brancher, multi-arm constructs Dual labels, multivalent probes, capture + reporter designs
Dendrimeric Oligonucleotide Higher-generation tree-like scaffold with many terminal groups PAMAM, PPI, Bis-MPA, lysine dendrons High payload density, delivery systems, nanomaterial interfaces
Design Options

Define Domains, Linkers, Conjugation Chemistry and Release Criteria

A multimeric oligonucleotide quote is fastest when domain sequences, architecture, linker strategy, conjugation handles, scale, purification and QC expectations are defined upfront.

Parameter Options Design Guidance
Domain Type Aptamer, ASO, siRNA, capture probe, reporter probe, barcode, peptide-linked module Define each domain separately and specify whether domains are identical or different.
Architecture Linear, PEG-linked, peptide-linked, branched, bispecific, dendron-supported Choose based on spacing, valency, folding and analytical complexity.
Linkers / Scaffolds TEG, AEEA, C6, C12, PEG4-PEG24, peptide linkers, peptide scaffolds, dendrons Linker length and scaffold rigidity can affect binding, folding, steric access and delivery.
Conjugation Handles Amine, thiol, maleimide, azide, alkyne, DBCO, NHS ester, peptide-reactive handles Orthogonal handles support staged assembly of multifunctional constructs.
Backbone Chemistry DNA, RNA, 2'-OMe, LNA/BNA, phosphorothioate, mixed backbones Backbone selection affects stability, Tm, folding and nuclease resistance.
Purification RP-HPLC, IE-HPLC, PAGE, SEC, diafiltration Complex multimeric constructs often benefit from method-matched purification.
QC MS, analytical HPLC, PAGE, SEC, UV-Vis loading, Tm, binding or hybridization assay QC should match construct size, conjugation chemistry and intended application.
Project Workflow

From Application Goal to Delivered Multimeric Construct

Bio-Synthesis supports project planning from initial application and domain layout through synthesis, conjugation, purification, QC and delivery.

01

Define Application

Binding, delivery, RNAi, ASO, peptide conjugation, signal amplification or multifunctional use.

02

Review Architecture

Select domain orientation, linker spacing, scaffold, handles and conjugation route.

03

Synthesis & Assembly

Synthesize domains or full construct and perform staged conjugation when needed.

04

Purification & QC

Release with selected purification, analytical identity, purity and optional functional testing.

Analytical Strategy

QC for Multimeric Oligonucleotide Constructs

Multimeric oligos may be larger and more heterogeneous than standard single-domain oligos, especially when they include ASO/siRNA domains, peptide conjugates, staged conjugation, dendrons or multiple labels.

Recommended QC Matrix

Release testing may include analytical HPLC, PAGE, SEC, ESI-MS, MALDI-TOF, UV-Vis loading analysis, Tm, binding, hybridization or application-specific functional assays.

Identity Confirmation

ESI-MS or MALDI-TOF where compatible; larger constructs may require method review.

Purity Profile

HPLC, PAGE or SEC depending on charge, size, label count and conjugation route.

Loading Analysis

UV-Vis or other analytical approaches for dyes, ligands, redox tags, peptides or payloads.

Functional Testing

Optional binding, Tm, hybridization, RNAi or capture testing for application-specific confidence.

Scale

Research-scale development through larger custom production lots, depending on construct complexity.

Documentation

CoA, purity profile, identity confirmation and custom documentation available on request.

Storage

Store lyophilized material cold and protect fluorescent, redox or light-sensitive payloads.

Design Decision Guide

Start With the Biological Goal

Use the application goal to narrow the construct type before selecting linkers, scaffolds, conjugation handles and QC strategy.

Fast Selection Logic

Multimeric oligo projects are easiest to scope when the desired biological or assay outcome is clearly defined first.

Bio-Synthesis can then recommend linker spacing, domain orientation, peptide or PEG strategy, purification approach and analytical release criteria.

Need stronger binding?
Consider aptamer dimers, trimers or higher-order aptamer multimers.
Need two targets?
Consider bispecific aptamers or dual-domain recognition constructs.
Need delivery?
Consider aptamer-siRNA, aptamer-ASO or peptide-oligonucleotide conjugates.
Need payload density?
Consider branched or dendron-supported multimeric oligonucleotides.
Need signal amplification?
Consider multivalent reporter, capture or biosensor-oriented constructs.

FAQ

What information is needed for a quote?
Provide domain sequences, application, architecture, linker/spacer preference, conjugation handles, payloads, scale, purification, QC needs and intended use.
What is a multimeric oligonucleotide?
A multimeric oligonucleotide contains two or more synthetic nucleic acid sequences, aptamer domains or functional oligo modules joined by chemical bonds, linkers, branchers, dendrons, polymers or peptide scaffolds.
Can multimeric oligos include antisense or siRNA domains?
Yes. Multimeric constructs can include ASO domains, siRNA modules, aptamers, reporter domains, targeting ligands or peptide-linked components depending on application.
Can Bio-Synthesis make peptide-oligonucleotide conjugates?
Yes. Peptide-oligo conjugates can be designed using peptide linkers, peptide scaffolds, cell-penetrating peptides or targeting peptides with appropriate conjugation handles.
Is a multimeric oligo the same as a branched oligo?
No. Multimeric describes multiple oligo domains. Branched describes one possible physical arrangement where multiple arms extend from a branch point.
What purification is recommended?
 Purification depends on size, charge and conjugation chemistry. RP-HPLC, IE-HPLC, PAGE, SEC or diafiltration may be recommended.
More FAQ'sAll FAQ's
Before Requesting a Quote

Information Helpful for Multimeric Oligo Design

Application
Binding, ASO, siRNA, Delivery
Domains
Sequences & roles
Architecture
Linear, Branched, Dendron
Linker
PEG, Peptide, C6-C12
Payload
Dye, Ligand, Peptide, Cargo
QC
HPLC, PAGE, SEC, MS
Contact & Quote Request

Discuss Your Multimeric Oligonucleotide Project

Bio-Synthesis scientists can assist with application-driven design, domain layout, linker strategy, peptide or chemical conjugation route, payload compatibility, purification planning and analytical characterization. Share your multimeric oligo requirements to receive technical guidance and a customized quotation.
Request a Quote Speak to a Scientist

Need help before quoting?

Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)

Design Review

Application, domain orientation, spacing, folding, multivalency, peptide linkage and manufacturability.

Release Package

HPLC, PAGE, SEC, MS, UV-Vis loading, CoA and optional functional testing.

Selected Literature

Selected Literature & Scientific Background

Use this section to support scientific credibility while keeping the page focused on multimeric oligonucleotide design, aptamer multimers, aptamer-siRNA conjugates, peptide-oligonucleotide conjugates, targeted delivery and analytical verification.

  1. McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology. 2006;24(8):1005-1015.
  2. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nature Reviews Drug Discovery. 2010;9(7):537-550.
  3. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery. 2017;16(3):181-202.
  4. Dassie JP, Liu X-Y, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotechnology. 2009;27(9):839-849.
  5. Ni S, Zhuo Z, Pan Y, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Applied Materials & Interfaces. 2021;13(8):9500-9519.
  6. Li F, Zhang H, Wang Z, et al. Dynamic DNA assemblies mediated by binding-induced DNA strand displacement. Journal of the American Chemical Society. 2013;135(7):2443-2446.

Suggested page note: References are provided for scientific background. Final multimeric oligonucleotide design should be evaluated within the intended application, domain sequences, linker chemistry, peptide or scaffold design, purification method and QC requirements.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links